Advertisement

Topics

Lilly & Topas Sign Multi-Year Agreement for Autoimmune Disease Treatment Research

08:05 EDT 23 Aug 2017 | PharmPro

Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance.
Contributed Author: 
Topas Therapeutics
Topics: 

Original Article: Lilly & Topas Sign Multi-Year Agreement for Autoimmune Disease Treatment Research

NEXT ARTICLE

More From BioPortfolio on "Lilly & Topas Sign Multi-Year Agreement for Autoimmune Disease Treatment Research"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...